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ABSTRACT 
 
We have investigated the possible involvement of two intracellular phospholipase A2s, 
namely Group VIA calcium-independent phospholipase A2 (iPLA2-VIA) and Group IVA 
cytosolic phospholipase A2 (cPLA2α), in the regulation of human promonocytic U937 cell 
proliferation. Inhibition of iPLA2-VIA activity by either pharmacological inhibitors such as 
bromoenol lactone or methyl arachidonyl fluorophosphonate, or specific antisense technology 
strongly blunted U937 cell proliferation. In contrast, inhibition of cPLA2α had no significant 
effect on U937 proliferation. Evaluation of iPLA2-VIA activity in cell cycle-synchronized 
cells revealed highest activity at G2/M and late S phases, and lowest at G1. PC levels showed 
the opposite trend, peaking at G1 and being lowest at G2/M and late S. Reduction of U937 cell 
proliferation by inhibition of iPLA2-VIA activity was associated with arrest in G2/M and S 
phases. The iPLA2-VIA effects were found to be independent of the generation of free 
arachidonic acid or of one of its oxygenated metabolites, and may work through regulation 
of the cellular level of PC, a structural lipid which is required for cell growth/membrane 
expansion. 
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The phospholipase A2 (PLA2) superfamily constitutes a heterogeneous group of enzymes with 
distinct roles in cell function [1-5]. The common feature of these enzymes is that they all 
selectively hydrolyze the fatty acid at the sn-2 position of glycerophospholipids. However, it 
is becoming increasingly clear that PLA2s notably differ in substrate specificity, cofactor 
requirements for activity, and cellular localization [1-5]. Mammalian cells usually contain 
several PLA2s, and thus the challenge in recent years has been that of ascribing specific 
cellular functions to particular PLA2 forms. PLA2s are systematically classified into several 
group types, with many of them including various subgroups [5]. However, attending to 
biochemical commonalities, PLA2s are usually grouped into four major families, namely the 
Ca2+-dependent secreted enzymes, the Ca2+-dependent cytosolic enzymes (cPLA2), the Ca
2+-
independent cytosolic enzymes (iPLA2), and the platelet-activating factor acetyl hydrolases 
[1, 5].  
 
The iPLA2 family consists of two members in mammalian cells, designated iPLA2-VIA and 
iPLA2-VIB, of which the former is the best characterized [3,6,7]. Since its purification [8] 
and cloning [9, 10] in the mid nineties, iPLA2-VIA has attracted considerable interest due to 
the multiple roles and functions that this enzyme may serve in cells. Several splice variants of  
iPLA2-VIA co-exist in cells and thus it is conceivable that multiple regulation mechanisms 
exist for this enzyme, which may depend on cell type. Thus, iPLA2-VIA PLA2 may be a 
multi-faceted enzyme with multiple functions of various kinds (i.e. homeostatic, catabolic, 
and signaling) in different cells and tissues [3, 7].  
 
Several lines of evidence have suggested a key role for iPLA2-VIA in the control of the levels 
of phosphatidylcholine (PC) in cells by regulating basal deacylation/reacylation reactions. 
This is manifested by the significant reduction of the steady-state level of lysoPC that is 
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observed shortly after acute inhibition of iPLA2-VIA by cell treatment with bromoenol 
lactone (BEL) [11, 12]. In INS-1 insulinoma cells, acute inhibition of iPLA2-VIA reduces the 
relatively high content of lysoPC that these cells exhibit by about 25% [12], whereas in 
macrophage-like cell lines, the decrease is about 50-60% [11, 13, 14], suggesting that the 
dependence of PC metabolism on iPLA2-VIA may vary from cell to cell. In some cell types, 
particularly -but not uniquely- phagocytes [11, 13-19], reduction of the steady-state level of 
lysoPC slows the initial rate of incorporation of exogenous arachidonic acid (AA) into cellular 
phospholipids. In other studies, it has been shown that iPLA2-VIA may be coordinately 
regulated with CTP:phosphocholine cytidylyltransferase to maintain PC levels [20-23]. Given 
that PC is the major cellular glycerophospholipid present in mammalian cell membranes and 
thus serves a key structural role, we hypothesized that iPLA2-VIA may play an important role 
in processes such as cell proliferation where membrane phospholipid biogenesis has to occur. 
Thus we studied the possible involvement of iPLA2-VIA in the normal proliferative response 
of human promonocytic U937 cells, and compared it to that of another major intracellular 
PLA2, the AA-selective cPLA2α. Utilizing different strategies, we demonstrate here that 
iPLA2-VIA, but not cPLA2α, plays a key role in U937 cell proliferation by a mechanism that 
does not involve AA or one of its oxygenated metabolites. 
 
 
RESULTS 
iPLA2 inhibition slows U937 cell proliferation - Using RT-PCR, we have previously found 
that human promonocytic U937 cells express both cPLA2α and iPLA2-VIA but, strikingly, do 
not express Group V, Group X or any of the Group II sPLA2s [24]. Enzymatic activities 
corresponding to both cPLA2α and iPLA2-VIA can be readily detected in the U937 cells by 
utilizing specific enzyme assays and inhibitors [18, 25]. We began the current study by 
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investigating whether the activities of these two intracellular phospholipases are required for 
normal U937 cell growth (i.e. that induced by the serum present in the culture medium, in the 
absence of any other mitogenic stimulus). In the first place, the effect of various selective 
PLA2 inhibitors was examined. Fig. 1 shows that the selective cPLA2α inhibitor 
pyrrophenone [26] completely blocked the Ca2+-dependent PLA2 activity of U937 cell 
homogenates at concentrations as low as 0.5-1 µM. However, at these concentrations, 
pyrrophenone failed to exert any effect on the proliferation of U937 cells, as measured by a 
colorimetric staining assay (Fig. 1).  
 
 In contrast to pyrrophenone, the iPLA2 inhibitor BEL strongly blocked the growth of 
the U937 cells (Fig. 2). In these experiments, a BEL concentration of 5 µM was utilized to 
avoid the proapoptotic effect of this drug when used at higher concentrations [27-29]. We 
confirmed that at 5 µM, BEL significantly blunted cellular iPLA2 activity, as measured by an 
in vitro assay (Fig. 2). Collectively, the data in Figs. 1 and 2 are consistent with the 
involvement of iPLA2, but not cPLA2α, on U937 cell proliferation. Owing to the lack of 
specificity of BEL in cell-based assays [28], additional pharmacological evidence for the 
involvement of iPLA2 in U937 cell growth was obtained by using MAFP, a dual 
iPLA2/cPLA2 inhibitor that is structurally unrelated to BEL and pyrrophenone [30, 31]. 
Concentrations of MAFP that completely inhibited cellular Ca2+-independent PLA2 activity 
also led to strong inhibition of U937 cell growth (Fig. 3). Given that the pyrrophenone 
experiments established that cPLA2α is not critical for U937 cell growth, the inhibitory effect 
of MAFP seen in Fig. 3 can be attributed to inhibition of iPLA2.  
 
 To confirm iPLA2 involvement in U937 cell growth in a more definitive manner, the 
effect of an antisense oligonucleotide directed against iPLA2-VIA was evaluated. In these 
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experiments, this antisense produced a 70-75% decrease of both immunoreactive iPLA2-VIA, 
and markedly inhibited (30-40%) U937 cell proliferation (Fig. 4).  
 
Inhibition of iPLA2 does not induce cell death - Trypan blue assays after the different 
treatments leading to iPLA2 inhibition indicated no loss of viability, thus suggesting that 
necrotic cell death did not occur. To examine the possibility of apoptotic cell death, we 
utilized the annexin V-binding assay, which measures externalization of phosphatidylserine, a 
marker of apoptosis. Incubation of the U937 cells with 10 µM MAFP or 5 µM BEL for 24 h, 
conditions that result in inhibition of iPLA2 activity and cell growth as shown above (Figs. 2 
and 3), had no effect on the number of  annexin V-positive cells, which always remained 
below 12% of the total cell population. Antisense inhibition of iPLA2-VIA also did not 
increase the number of annexin V-positive cells. As a control for these experiments, we also 
studied the effect of a higher BEL concentration,  i.e. 25 µM, which is known to induce 
apoptotic cell death in U937 cells in an iPLA2-independent manner [27]. Confirming our 
previous data, 25 µM BEL increased the extent of apoptotic cell death well above 75% after 
a 24-h incubation period. Together, these data indicated that the slowed growth of cells 
deficient in iPLA2 activity by either pharmacological or antisense means arises as a result of 
slowed cell division and not of increased apoptosis. 
 
iPLA2 Activity During the Cell Cycle - To gain more information on the role of iPLA2 on 
U937 cell growth, we used flow cytometry to examine the cell cycle dependence of iPLA2 
activity in the U937 cells.  The cells were synchronized with nocodazole [23, 32] and then 
allowed to progress through the cell cycle under normal culture conditions. Immediately after 
release from the mitotic block with nocodazole, more than 75% of the cells were in G2/M 
(Fig. 5). The cells were in G1 from 2 to 8 h after release from nocodazole, and in S thereafter 
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up to 10 h. After 10 h the cells became largely asynchronous again. Thus, this method allows 
study of the cell cycle of U937 cells in G2/M throughout G1 and S phases [23, 32]. 
 iPLA2 activity measurements along the cell cycle revealed significant differences 
depending on the phase where the cells were (Fig. 5). Highest activity was found during 
G2/M, decreasing as the cells entered G1 and then increasing again as the cells approached and 
entered S phase. Of note, the same pattern of variation of iPLA2 activity along the cell cycle 
was detected whether the assay was conducted with mixed micelles, vesicles, or natural 
membranes as substrates (not shown), thus confirming the biological relevance of the 
findings. Importantly, quantification of the levels of PC, the major membrane phospholipid in 
mammalian cells, during the cell cycle showed a pattern that was clearly opposite to that 
found for iPLA2 activity (Fig. 5). PC levels rose abruptly in early G1 and then slowly declined 
as the cells were progressing into late G1 and S (Fig. 5). That PC mass and iPLA2 activity 
show opposite kinetics is fully consistent with the possibility that iPLA2 behaves as a major 
regulator of PC catabolism, which is responsible for glycerophospholipid accumulation 
during the cell cycle [23, 33]. Thus, decreased iPLA2 activity during phase G1 would result in 
an increase in PC mass due to reduced catabolism. 
 
Induction of  cell cycle arrest by iPLA2 inhibition - Having established that iPLA2 activity 
is cell-cycle regulated, the levels of which inversely correlate with those of the major 
membrane phospholipid PC, we set out to investigate next whether the slowed growth due to 
iPLA2 inhibition was a consequence of cell cycle arrest. The cells were synchronized with 
nocodazole and then treated with BEL to inhibit iPLA2 activity. Pyrrophenone was also used 
as a control. Fig. 6 shows that treatment of the cells with BEL induced a significant 
accumulation of cells in G2/M and S, and a concomitant decrease of cells in G1, with respect 
to untreated cells. Pyrrophenone, on the contrary, induced no significant changes in the phase 
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distribution (Fig. 6). Thus these data suggest that inhibition of iPLA2, but not cPLA2α, causes 
cell arrest in S and G2/M phases.  
 
Arachidonic acid and/or its metabolites are not involved in U937 cell growth - In addition 
to its role in PC homeostasis, iPLA2, as a sn-2 lipase, may also participate in generating free 
fatty acids such as AA, which could subsequently be metabolized to eicosanoids. The 
importance of AA and the eicosanoids as growth factors towards various cell types has 
previously been demonstrated [34]. We tested first the effects of various cyclooxygenase and 
lipoxygenase inhibitors on the growth of U937 cells under normal culture conditions. The 
inhibitors employed were aspirin (up to 25 µM), indomethacin (up to 25 µM), NS-398 (up to 
10 µM), ebselen (up to 10 µM), baicalein (up to 10 µM), MK-886 (up to 10 µM), and 
nordihydroguaiaretic acid (up to 10 µM). Control experiments had indicated that at the 
concentrations employed, these inhibitors effectively blocked AA oxygenation by the 
cyclooxygenase and lipoxygenase pathways. None of the inhibitors exerted any significant 
effect on U937 cell growth (data not shown). We studied next whether adding 10 µM AA to 
the cell cultures attenuates the antiproliferative effect of inhibiting iPLA2 by BEL or antisense 
technology. The results indicated however that AA failed to restore the growth of cells 
deficient in iPLA2 activity. Moreover, when the cells were synchronized with nocodazole, the 
subsequent addition of exogenous AA exerted no detectable effect on the observed phase 
distribution (see Fig. 6), whether the cells had been treated or not with BEL (not shown). 
Collectively, these results suggest that AA or a metabolite does not mediate the effect of 
iPLA2 on U937 cell proliferation. 
 
DISCUSSION 
In this study we demonstrate that iPLA2-VIA is required for the proliferation of human 
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promonocytic U937 cells under normal culture conditions (i.e. in the absence of any 
mitogenic stimulus other than serum), and that inhibition of iPLA2-VIA by either 
pharmacological means or antisense technology slows growth by inducing arrest at S and 
G2/M phases. Cell accumulation at these phases of the cell cycle could not be reversed by 
supplying the medium with exogenous AA, indicating that the iPLA2-VIA role is not 
mediated via AA-derived mitogenic signaling. We also document that U937 cell iPLA2-VIA 
activity is regulated in a cell cycle dependent manner, with maximal activity at G2/M, steadily 
declining during G1, and rising up at late S phase. Strikingly, the levels of PC, the major 
membrane phospholipid in mammalian membranes, exhibit the opposite kinetics, with the 
highest levels at G1. This inverse relationship between the kinetics of iPLA2-VIA activity and 
PC accumulation agrees with previous studies in Jurkat cells [32] and CHO-K1 cells [23]. It is 
well established that changes in PC content during the cell cycle correlate better with the 
kinetics of its catabolism rather than synthesis [23, 33, 35], and the involvement of iPLA2-
VIA in the homeostatic regulation of membrane phospholipid turnover is one of the first roles 
attributed to this enzyme in cells [6, 7].  Thus our results are in line with a scenario whereby 
iPLA2-VIA plays a central role in cell growth and division by regulating glycerophospholipid 
metabolism during the cell cycle [23, 32, 36]. Thus, down-regulation of iPLA2-VIA activity 
in G1 and early S would allow for accumulation of phospholipid in preparation for future cell 
division. Once cells enter S phase, iPLA2-VIA begins to increase, which would slow down 
phospholipid accumulation. It is interesting to note, however, that iPLA2-VIA may not 
always be the major regulator of phospholipid catabolism during cell cycle progression. 
Our data suggest that two hours after cell entry, iPLA2 is drastically reduced but PC 
levels appear to barely change (Fig. 5), raising the possibility that, at this time, 
involvement of fatty acid-reacylating enzyme activities or inter-
phospholipid/diacylglycerol transacylation might be significant in regulating PC levels. 
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  Whether in addition to regulating glycerophospholipid metabolism during the cell 
cycle, iPLA2-VIA may also act by activating receptor-mediated mitogenic signaling --e.g. by 
directly mediating the generation of lipid mediators with growth factor-like properties-- is 
also a possibility that deserves consideration. Although we and others [23, 32, 37] find no 
evidence for the involvement of AA and/or its metabolites in regulating cellular proliferation, 
other studies have reported the involvement of iPLA2 in cell growth via generation of AA, 
clearly indicating cell type-specific differences. In a recent study  Herbert and Walker [38] 
have described the involvement of iPLA2-VIA in the proliferative response of human 
umbilical endothelial cells to serum. Inhibition of iPLA2-VIA blocked proliferation, which 
could be partially restored by supplying the cell cultures with exogenous AA [38]. Similarly, 
work by Sánchez and Moreno [39] has attributed a key role for iPLA2-VIA-mediated AA 
release in regulating Caco-2 cell growth.  
 While our results have excluded the eicosanoids from having effects on cell cycle 
progression, we do not rule out the possibility that lysophospholipids generated by 
iPLA2-VIA could be involved in the response. As a matter of fact, iPLA2-VIA has been 
shown to mediate various responses of monocytes and U937 cells through 
lysophospholipid generation, namely secretion [10], apoptosis [24, 40, 41] and possibly 
chemotaxis [42, 43]. 
 The involvement of specific PLA2 forms in the regulation of cell division may also be 
a cell type-specific event. Although we have failed to implicate cPLA2α --a well established 
signal-activated enzyme [34]-- in regulating cellular proliferation, other studies have reported 
the involvement of this enzyme. In the aforementioned system of human umbilical endothelial 
cells, the importance of the cPLA2α-mediated AA release in the regulation of cell 
proliferation has also been documented [44]. Thus the suggestion was made that both 
enzymes may somehow cooperate in regulating endothelial cell proliferation via generation of 
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AA [38, 44]. In contrast, the work by Sánchez and Moreno [39] attributed a key role for 
iPLA2-VIA-mediated AA release in regulating Caco-2 cell growth, but ruled out a role for 
cPLA2α in the process. However, studies in vascular smooth muscle cells by Anderson et al. 
[45] highlighted the very important role of cPLA2α in the process but the lack of involvement 
of iPLA2-VIA. Importantly, in a recent study with neuroblastoma cells, van Rossum et al. [46] 
demonstrated the involvement of cPLA2α in cell cycle progression and, although in the latter 
study a role for iPLA2 in this system could not be ascertained, the observation was made that 
redundancy of functions between cPLA2 and iPLA2 may exist under certain conditions. We 
are currently performing experiments with different cell systems to study the possibility of 
cross-talk between cPLA2α and iPLA2-VIA in cell proliferation, and also to define when and 
whether the role of iPLA2-VIA in cell growth is to directly generate growth factor-like lipids 
and/or to regulate changes in overall phospholipid metabolism that could trigger the activation 
in situ of intracellular mitogenic pathways.  
 
  
EXPERIMENTAL PROCEDURES 
Reagents. [5,6,8,9,11,12,14,15-3H]AA (200 Ci/mmol) was purchased from Amersham Ibérica 
(Madrid, Spain). Methyl arachidonyl fluorophosphonate (MAFP), bromoenol lactone (BEL), 
and the human iPLA2-VIA antibody were from Cayman (Ann Arbor, MI, USA). 
Pyrrophenone was kindly provided by Dr. T. Ono (Shionogi, Japan). All other reagents were 
from Sigma (St. Louis, MO, USA). 
 
Cell culture. U937 cells were kindly provided by Dr. Patricio Aller (Centro de 
Investigaciones Biológicas, Madrid, Spain). The cells were maintained in RPMI 1640 
medium supplemented with 10% (v/v) fetal calf serum, 2 mM glutamine, penicillin (100 
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units/ml) and streptomycin (100 µg/ml) [47]. For experiments, the cells were incubated at 
37°C in a humidified atmosphere of CO2/air (1:19) at a cell density of 0.5-1 x 10
6 cells/ml in 
12-well plastic culture dishes (Costar).  
 
PLA2 activity assays. For Ca
2+-dependent PLA2 activity, the mammalian membrane assay 
described by Diez et al. [48] was used. Briefly, aliquots of U937 cell homogenates were 
incubated for 1-2 h at 37°C in 100 mM HEPES (pH 7.5) containing 1.3 mM CaCl2 and 
100,000 dpm of [3H]AA-labeled U937 cell membrane, used as substrate, in a final volume of 
0.15 ml. Prior to assay, the cell membrane substrate was heat at 57°C for 5 min, in order 
to inactivate coenzyme A-independent transacylase activity [48]. The assay contained 25 
µM LY311727 and 25 µM BEL to completely inhibit endogenous secreted and Ca2+-
independent PLA2 activities [30, 49-51]. After lipid extraction, free [
3H]arachidonic acid 
was separated by thin-layer chromatography, using n-hexane/ethyl ether/acetic acid 
(70:30:1) as a mobile phase [52, 53]. For Ca2+-independent PLA2 activity, U937 cell aliquots 
were incubated for 2 h at 37°C in 100 mM Hepes (pH 7.5) containing 5 mM EDTA and 100 
µM labeled phospholipid substrate (1-palmitoyl-2-[3H]palmitoyl-glycero-3-phosphocholine, 
sp. act. 60 Ci/mmol, American Radiolabeled Chemicals, St. Louis, MO) in a final volume of 
150 µl. The phospholipid substrate was used in the form of sonicated vesicles in buffer. The 
reactions were quenched by adding 3.75 volumes of chloroform/methanol (1:2). After lipid 
extraction, free [3H]palmitic acid was separated by thin-layer chromatography, using n-
hexane/ethyl ether/acetic acid (70:30:1) as a mobile phase [52, 53].  In some experiments 
iPLA2 activity was also measured utilizing a mixed-micelle substrate or the natural membrane 
assay.  For the mixed micelle assay, Triton X-100 was added to the dried lipid substrate at a 
molar ratio of 4:1. Buffer was added and the mixed micelles were made by a combination of 
heating above 40°C, vortexing, and water bath sonication until the solution clarified. The 
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natural membrane assay was carried out exactly as described above except that CaCl2 was 
omitted and 5 mM EDTA was added instead. All of these assay conditions have been 
validated previously for the U937 cell homogenates [18, 25, 54].  
 
Proliferation assay. The CellTiter96 Aqueous One Solution Cell Proliferation assay 
(Promega) was used, following the manufacturer’s instructions. Briefly, cells (10,000 cells per 
well) were seeded in 96-well plates treated with vehicle or different concentrations of 
inhibitor. After 24 h, formazan product formation was assayed by recording absorbance at 490 
mn with a 96-well plate reader. 
 
Antisense oligonucleotide treatments. The iPLA2-VIA antisense oligonucleotide utilized in 
this study has been described in previous studies from our laboratory  [24, 25, 27, 55]. The 
antisense or sense oligonucleotides were mixed with lipofectamine, and complexes were 
allowed to form at room temperature for 10-15 min. The complexes were then added to the 
cells, and the incubations were allowed to proceed under standard cell culture conditions. The 
final concentrations of oligonucleotide and lipofectamine were 1 µM and 10 µg/ml, 
respectively. Oligonucleotide treatment and culture conditions were not toxic for the cells as 
assessed by the Trypan blue dye exclusion assay. 
 
Immunoblot analyses. Cells were lysed in an ice-cold lysis buffer, and 15 µg of cellular 
protein from each sample were separated by standard 10% SDS-PAGE and transferred to 
nitrocellulose membranes. Dilution of both primary and secondary antibodies was made in 
phosphate-buffered saline containing 0.5% defatted dry milk and 0.1% Tween 20. After 1 h 
incubation with primary antibody at 1:1000, blots were washed 3 times and an anti-rabbit 
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secondary peroxidase-conjugated antibody was added for another h. Immunoblots were 
developed using the Amersham ECL system. 
 
Cell synchronization and cell cycle analysis. U937 cells were synchronized at G2/M by 
treating them with 0.05 µg/ml nocodazole for 12 h [32]. The cells were then washed, plated in 
fresh medium and allowed to progress through the cell cycle. After the indicated times, the 
cells were washed twice with cold PBS, and fixed with 70% ethanol at 4°C for 18 h. Cells 
were then washed and resuspended in PBS. RNA was removed by digestion with RNase A at 
room temperature. Staining was achieved by incubation with staining solution (500 µg/ml 
propidium iodide in PBS) for 1 h and cell cycle analysis was performed by flow cytometry in 
a Coulter Epics XL-MCL cytofluorometer.  
 
PC mass quantification. Cell lipids were extracted by the Bligh and Dyer procedure [56], and 
the individual phospholipid species were fractionated by TLC in silica gel G plates using 
chloroform/methanol/acetic acid/water (65:501:4) as a solvent system [57]. The PC fraction 
was identified by comparison with commercial standards. PC mass was quantified by 
measuring lipid phosphorus [58].  
 
 
ACKNOWLEDGEMENTS 
We thank Montse Duque and Yolanda Sáez for expert technical assistance. This work was 
supported by the Spanish Ministry of Education and Science (Grants BFU2004-01886/BMC, 
SAF2004-04676, BFU2007-67154/BMC, and SAF2007-60055), and the Fundación La Caixa 
(Grant BM05-248-0). 
 15 
REFERENCES 
 
1.  Balsinde J, Winstead MV & Dennis, E. A. (2002) Phospholipase A2 regulation of 
arachidonic acid mobilization. FEBS Lett. 531, 2-6.  
2.  Balboa MA, Varela-Nieto I, Lucas KK, & Dennis EA (2002) Expression and function 
of phospholipase A2 in brain. FEBS Lett. 531, 12-17.  
3.  Balsinde J, & Balboa MA (2005) Cellular regulation and proposed biological 
functions of group VIA calcium-independent phospholipase A2 in activated cells. Cell. 
Signal. 17, 1052-1062.  
4.  Balboa MA and Balsinde J (2006) Oxidative stress and arachidonic acid mobilization. 
Biochim. Biophys. Acta 1761, 385-391.  
5.  Schaloske R and Dennis EA (2006). The phospholipase A2 superfamily and its group 
numbering system. Biochim. Biophys. Acta 1761, 1246-1259. 
6. Balsinde J & Dennis EA (1997) Function and inhibition of intracellular calcium-
independent phospholipase A2. J. Biol. Chem. 272, 16069-16072. 
7. Winstead MV, Balsinde J, & Dennis EA (2000) Calcium-independent phospholipase 
A2. Structure and function. Biochim. Biophys. Acta 1488, 28-39. 
8. Ackermann EJ, Kempner ES, & Dennis EA (1994) Ca2+-independent cytosolic 
phospholipase A2 from macrophage-like P388D1 cells. Isolation and characterization. 
J. Biol. Chem. 269, 9227-9233. 
9. Tang J, Kriz RW, Wolfman N, Shaffer M, Seehra J, & Jones, SS (1997) A novel 
cytosolic calcium-independent phospholipase A2 contains eight ankyrin motifs. J. 
Biol. Chem. 272, 8567-8580. 
10.  Balboa, MA, Balsinde J, Jones SS, and Dennis EA (1997) Identity between the Ca2+-
independent phospholipase A2 enzymes from P388D1 macrophages and Chinese 
 16 
hamster ovary cells. J. Biol. Chem. 272, 8576-8580.  
11. Balsinde J, Barbour SE, Bianco ID, & Dennis EA (1994) Arachidonic acid 
mobilization in P388D1 macrophages is controlled by two distinct Ca
2+-dependent 
phospholipase A2 enzymes. Proc. Natl. Acad. Sci. U.S.A. 91, 11060-11064. 
12 Ramanadham S, Hsu FF, Bohrer A, Ma Z, & Turk J (1999) Studies of the role of 
group VI phospholipase A2 in fatty acid incorporation, phospholipid remodeling, 
lysophosphatidylcholine generation, and secretagogue-induced arachidonic acid 
release in pancreatic islets and insulinoma cells. J. Biol. Chem. 274, 13915-13927.  
13. Balsinde J, Balboa MA, & Dennis EA (1997) Antisense inhibition of group VI Ca2+-
independent phospholipase A2 blocks phospholipid fatty acid remodeling in murine 
P388D1 macrophages. J. Biol. Chem. 272, 29317-29321 
14. Balboa MA, Sáez Y, & Balsinde J. (2003) Calcium-independent phospholipase A2 is 
required for lysozyme secretion in U937 promonocytes. J. Immunol. 170, 5276–5280.  
15. Daniele JJ, Fidelio GD & Bianco, ID (1999) Calcium dependency of arachidonic acid 
incorporation into cellular phospholipids of different cell types. Prostaglandins 57, 
341-350. 
16. Alzola E, Perez-Etxebarria A, Kabre E, Fogarty DJ, Metioui M, Chaib N, Macarulla 
JM., Matute C, Dehaye JP, & Marino A (1998) Activation by P2X7 agonists of two 
phospholipases A2 (PLA2) in ductal cells of rat submandibular gland. Coupling of the 
calcium-independent PLA2 with kallikrein secretion. J. Biol. Chem. 273, 30208-
30217. 
17. Birbes H, Drevet S, Pageaux JF, Lagarde M, & Laugier C. (2000) Involvement of 
calcium-independent phospholipase A2 in uterine stromal cell phospholipid 
remodeling. Eur. J. Biochem. 267, 7118-7127. 
 17 
18. Balsinde J (2002) Roles of various phospholipases A2 in providing lysophospholipid 
acceptors for fatty acid phospholipid incorporation and remodelling. Biochem. J. 364, 
695-702.  
19. Pérez R, Melero R, Balboa MA, & Balsinde J. (2004) Role of group VIA calcium-
independent phospholipase A2 in arachidonic acid release, phospholipid fatty acid 
incorporation, and apoptosis in U937 cells responding to hydrogen peroxide J. Biol. 
Chem. 279, 40385-40391.  
20. Baburina I, & Jackowski S. (1999) Cellular responses to excess phospholipid. J. Biol. 
Chem. 274, 9400-9408. 
21. Barbour SE, Kapur A & Deal CL (1999) Regulation of phosphatidylcholine 
homeostasis by calcium-independent phospholipase A2. Biochim Biophys Acta 1439, 
77-88.  
22. Walkey CJ, Kalmar GB, & Cornell RB (1994) Overexpression of rat liver 
CTP:phosphocholine cytidylyltransferase accelerates phosphatidylcholine synthesis 
and degradation. J. Biol. Chem. 269, 5742-5749. 
23. Manguikian AD & Barbour SE (2004) Cell cycle dependence of Group VIA calcium-
independent phospholipase A2 activity. J. Biol. Chem. 279, 52881-52892. 
24. Pérez R, Balboa MA & Balsinde J (2006) Involvement of group VIA calcium-
independent phospholipase A2 in macrophage engulfment of hydrogen peroxide-
treated U937 cells. J. Immunol. 176, 2555–2561.  
25. Balboa MA & Balsinde J. (2002) Involvement of calcium-independent phospholipase 
A2 in hydrogen peroxide-induced accumulation of free fatty acids in human U937 
cells. J. Biol. Chem. 277, 40384-40389.  
26. Ono T, Yamada K., Chikazawa Y., Ueno M., Nakamoto S, Okuno T & Seno K (2002) 
Characterization of a novel inhibitor of cytosolic phospholipase A2α. Biochem. J. 363, 
 18 
727-735. 
27. Fuentes L, Pérez R, Nieto ML, Balsinde J, & Balboa MA (2003) Bromoenol lactone 
promotes cell death by a mechanism involving phosphatidate phosphohydrolase-1 
rather than calcium-independent phospholipase A2. J. Biol. Chem. 278, 44683-44690.  
28. Balsinde J, Pérez R, & Balboa MA. (2006) Calcium-independent phospholipase A2 
and apoptosis. Biochim. Biophys. Acta 1761, 1344-1350.  
29. Pindado J, Balsinde J, & Balboa MA (2007) TLR3-dependent induction of nitric oxide 
synthase in RAW 264.7 macrophage-like cells via a cytosolic phospholipase 
A2/cyclooxygenase-2 pathway. J. Immunol. 179, 4821-4828. 
30. Balsinde J & Dennis EA (1996) Distinct roles in signal transduction for each of the 
phospholipase A2 enzymes present in P388D1 macrophages. J. Biol. Chem. 271, 6758-
6765. 
31. Lio YC, Reynolds LJ,  Balsinde J, & Dennis EA. (1996) Irreversible inhibition of 
Ca2+-independent phospholipase A2 by methyl arachidonyl fluorophosphonate. 
Biochim. Biophys. Acta 1302, 55-60. 
32. Roshak AK, Capper EA, Stevenson C, Eichman C, & Marshall LA. (2000) Human 
calcium-independent phospholipase A2 mediates lymphocyte proliferation. J. Biol. 
Chem. 275, 35692-35698. 
33. Jackowski S (1996) Cell cycle regulation of membrane phospholipid metabolism. J. 
Biol. Chem. 271, 20219-20222. 
34. Nakanishi M & Rosenberg DW (2006) Roles of cPLA2α and arachidonic acid in 
cancer. Biochim Biophys Acta 1761, 1335-1343 
35. Golfman LS, Bakovic M, & Vance DE (2001) Transcription of the 
CTP:phosphocholine cytidylyltransferase alpha gene is enhanced during the S phase 
of the cell cycle. J. Biol. Chem. 276, 43688-43692. 
 19 
36. Song Y, Wilkins P,  Hu W, Murthy KS, Chen J, Lee Z, Oyesanya R, Wu J,  Barbour 
SE & Fang X. (2007) Inhibition of calcium-independent phospholipase A2 suppresses 
proliferation and tumorigenicity of ovarian carcinoma cells. Biochem. J. 406, 427-436. 
37. Zhang XH, Zhao C,  Seleznev K, Song K,  Manfredi JJ & Ma ZA (2006) Disruption 
of G1-phase phospholipid turnover by inhibition of Ca
2+-independent phospholipase 
A2 induces a p53-dependent cell-cycle arrest in G1 phase. J. Cell. Sci. 119, 1005-1015. 
38. Herbert SP & Walker JH (2006) Group VIA calcium-independent phospholipase A2 
mediates endothelial cell progression. J. Biol. Chem. 281, 35709-35716 
39. Sánchez T & Moreno JJ (2002) Calcium-independent phospholipase A2 through 
arachidonic acid mobilization is involved in Caco-2 cell growth. J. Cell. Physiol. 193, 
293-298. 
40. Lauber K,  Bohn E, Krober SM, Xiao YJ, Blumenthal SG, Lindemann RK, Marini P,  
Wiedig C, Zobywalski A. Baksh S, Xu Y, Autenrieth IB, Schulze-Osthoff K, Belka C,  
Stuhler G & Wesselborg S. (2003) Apoptotic cells induce migration of phagocytes via 
caspase-3-mediated release of a lipid attraction signal. Cell 113, 717-730. 
41. Kim SJ,  Gershov D, Ma X, Brot N & Elkon KB (2002) I-PLA2 activation during 
apoptosis promotes the exposure of membrane lysophosphatidylcholine leading to 
binding by natural immunoglobulin M antibodies and complement activation. J. Exp. 
Med. 196, 655-665. 
42. Carnevale KA & Cathcart MK (2001) Calcium-independent phospholipase A2 is 
required for human monocyte chemotaxis to monocyte chemoattractant protein 1. J. 
Immunol. 167, 3414-3421. 
43. Mishra RS, Carnevale KA & Cathcart MK (2008) iPLA2β: front and center in human 
monocyte chemotaxis to MCP-1. J. Exp. Med. (10.1084/jem.20071243). 
44. Herbert SP, Ponnambalam S & Walker JH (2005) Cytosolic phospholipase A2α 
 20 
mediates endothelial cell proliferation and is inactivated by association with the Golgi 
apparatus. Mol. Biol. Cell 16, 3800-3809.  
45. Anderson KA, Roshak A, Winkler JD, McCord M & Marshall LA (1997) Cytosolic 
85-kDa phospholipase A2-mediated release of arachidonic acid is critical for 
proliferation of vascular smooth muscle cells. J. Biol. Chem. 272, 30504-30511. 
46. van Rossum GSAT, Bijvelt JJM, van den Bosch H, Verkleij AJ & Boonstra J (2002) 
Cytosolic phospholipase A2 and lipoxygenase are involved in cell cycle progression in 
neuroblastoma cells. Cell. Mol. Life Sci. 59, 181-188. 
47. Balsinde J & Mollinedo F (1991) Platelet-activating factor synergizes with phorbol 
myristate acetate in activating phospholipase D in the human promonocytic cell line 
U937. Evidence for different mechanisms of activation. J. Biol. Chem. 266, 18726-
18730. 
48. Diez E,  Chilton FH, Stroup G, Mayer RJ, Winkler JD & Fonteh AN. (1994) Fatty 
acid and phospholipid selectivity of different phospholipase A2 enzymes studied by 
using a mammalian membrane as substrate. Biochem. J. 301, 721-726. 
49.  Schevitz RW, Bach NJ, Carlson DG, Chirgadze NY, Clawson DK, Dillard RD, 
Draheim SE, Hartley LW, Jones ND, Mihelich ED, et al. (1995) Structure-based 
design of the first potent and selective inhibitor of human non-pancreatic secretory 
phospholipase A2. Nat Struct Biol. 2, 458-465. 
50.  Hazen SL, Zupan LA, Weiss RH, Getman DP, & Gross RW (1991) Suicide inhibition 
of canine myocardial cytosolic calcium-independent phospholipase A2. Mechanism-
based discrimination between calcium-dependent and -independent phospholipases 
A2. J. Biol. Chem. 266, 7227-7232. 
51.  Balsinde J, Balboa MA, Insel PA & Dennis EA (1999) Regulation and inhibition of 
phospholipase A2. Annu. Rev. Pharmacol. Toxicol. 39, 175-189. 
 21 
52.  Diez E., Balsinde J., Aracil M & Schüller A (1987) Ethanol induces release of 
arachidonic acid but not synthesis of eicosanoids in mouse peritoneal macrophages. 
Biochim Biophys Acta. 921, 82-89. 
53.  Balsinde J, Fernández B., Solís-Herruzo JA & Diez E (1992) Pathways for 
arachidonic acid mobilization in zymosan-stimulated mouse peritoneal macrophages. 
Biochim Biophys Acta. 1136, 75-82. 
54. Balboa MA, Pérez R & Balsinde J (2003) Amplification mechanisms of inflammation: 
paracrine stimulation of arachidonic acid mobilization by secreted phospholipase A2 is 
regulated by cytosolic phospholipase A2-derived hydroperoxyeicosatetraenoic acid. J 
Immunol. 171, 989-994. 
55.  Pérez R, Matabosch X, Llebaria A, Balboa MA & Balsinde J (2006) Blockade of 
arachidonic acid incorporation into phospholipids induces apoptosis in U937 
promonocytic cells. J. Lipid Res. 47, 484-491.  
56. Bligh EG & Dyer WJ (1959) A rapid method of total lipid extraction and purification. 
Can. J. Biochem. Physiol. 37, 911-917. 
57. Balsinde J, Diez E, Schüller A, & Mollinedo F. (1988) Phospholipase A2 activity in 
resting and activated human neutrophils. Substrate specificity, pH dependence, and 
subcellular localization. J. Biol. Chem. 263, 1929-1936.  
58. Rouser G, Fleischer S & Yamamoto A (1970) Two dimensional thin layer 
chromatographic separation of polar lipids and determination of phospholipids by 
phosphorus analysis of spots. Lipids 8: 494-496.  
 
 22 
FIGURE CAPTIONS 
 
Figure 1. Effect of pyrrophenone on the growth of U937 cells. A, Dose-response of the effect 
of pyrrophenone on the Ca2+-dependent PLA2 activity of U937 cell homogenates. The cell 
membrane assay was utilized. B, Time-course of the effect of pyrrophenone on the 
proliferative capacity of U937 cells. The cells were incubated with (closed bars) or without 
(open bars) 1 µM pyrrophenone for the times indicated, Afterward, cell number was estimated 
as described under Experimental Procedures. Data are given as means ± S.E.M. of triplicate 
determinations, representative of three independent experiments. 
 
Figure 2. Effect of BEL on the growth of U937 cells. A, Dose-response of the effect of BEL 
on the Ca2+-independent PLA2 activity of U937 cell homogenates. The substrate was 
presented in the form of mixed micelles with Triton X-100. B, Time-course of the effect of 
BEL on the proliferative capacity of U937 cells. The cells were incubated with (closed bars) 
or without (open bars) 5 µM BEL for the times indicated, Afterward, cell number was 
estimated as described under Experimental Procedures. Data are given as means ± S.E.M. of 
triplicate determinations, representative of three independent experiments. 
 
Figure 3. Effect of MAFP on the growth of U937 cells. A, Dose-response of the effect of 
MAFP on the Ca2+-independent PLA2 activity of U937 cell homogenates. The Substrate was 
presented in the form of mixed micelles with Triton X-100. B, Time-course of the effect of 
MAFP on the proliferative capacity of U937 cells. The cells were incubated with (closed bars) 
or without (open bars) 10 µM MAFP for the time indicated, Afterward, cell number was 
estimated as described under Experimental Procedures. Data are given as means ± S.E.M. of 
triplicate determinations, representative of three independent experiments. 
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Figure 4. Antisense inhibition of iPLA2-VIA slows the growth of U937 cells. The cells were 
either untreated (inverted triangles), or treated with sense (open circles) or antisense (closed 
circles) oligonucleotides. Afterward, cell number was estimated as described under 
Experimental Procedures. Inset shows the iPLA2-VIA protein level after the different 
treatments (C, control cells, S, sense-treated cells, A, antisense-treated cells), as analyzed by 
immunoblot. Data are given as mean ± range of duplicate determinations, representative 
of five independent experiments. 
 
Figure 5. Changes in iPLA2 activity and PC mass during the cell cycle. The cells were 
synchronized with nocodazole as described under Experimental Procedures. iPLA2 activity 
and PC mass were measured at various times after releasing the cells from the nocodazole 
block, as indicated. Data are given as mean ± S.E. of triplicate determinations, 
representative of five independent experiments. 
 
Figure 6.  Effect of BEL and pyrrophenone on the U937 cell cycle. The cells were 
synchronized with nocodazole as described under Experimental Procedures. After releasing 
the cells from the nocodazole block they were untreated (open symbols) or treated with 5 µM 
BEL (closed symbols, left column) or 1 µM pyrrophenone (closed symbols, right column), 
and the percent of cells at various phases of the cell cycle was studied by flow cytometry at 
different times. Data are given as mean ± range of duplicate determinations, 
representative of three independent experiments. 
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